We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Amgen (AMGN) Gains But Lags Market: What You Should Know
Read MoreHide Full Article
In the latest trading session, Amgen (AMGN - Free Report) closed at $188.10, marking a +0.12% move from the previous day. This change lagged the S&P 500's 1.86% gain on the day. Meanwhile, the Dow gained 1.63%, and the Nasdaq, a tech-heavy index, added 2.95%.
Prior to today's trading, shares of the world's largest biotech drugmaker had lost 9.16% over the past month. This has was narrower than the Medical sector's loss of 10.01% and lagged the S&P 500's loss of 8.85% in that time.
AMGN will be looking to display strength as it nears its next earnings release, which is expected to be October 30, 2018. On that day, AMGN is projected to report earnings of $3.42 per share, which would represent year-over-year growth of 4.59%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $5.82 billion, up 0.74% from the year-ago period.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $14.02 per share and revenue of $23.25 billion. These totals would mark changes of +11.45% and +1.78%, respectively, from last year.
It is also important to note the recent changes to analyst estimates for AMGN. These revisions help to show the ever-changing nature of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.41% higher within the past month. AMGN is holding a Zacks Rank of #2 (Buy) right now.
Digging into valuation, AMGN currently has a Forward P/E ratio of 13.4. This represents a discount compared to its industry's average Forward P/E of 26.
Also, we should mention that AMGN has a PEG ratio of 1.82. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. Medical - Biomedical and Genetics stocks are, on average, holding a PEG ratio of 1.78 based on yesterday's closing prices.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 85, which puts it in the top 33% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Amgen (AMGN) Gains But Lags Market: What You Should Know
In the latest trading session, Amgen (AMGN - Free Report) closed at $188.10, marking a +0.12% move from the previous day. This change lagged the S&P 500's 1.86% gain on the day. Meanwhile, the Dow gained 1.63%, and the Nasdaq, a tech-heavy index, added 2.95%.
Prior to today's trading, shares of the world's largest biotech drugmaker had lost 9.16% over the past month. This has was narrower than the Medical sector's loss of 10.01% and lagged the S&P 500's loss of 8.85% in that time.
AMGN will be looking to display strength as it nears its next earnings release, which is expected to be October 30, 2018. On that day, AMGN is projected to report earnings of $3.42 per share, which would represent year-over-year growth of 4.59%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $5.82 billion, up 0.74% from the year-ago period.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $14.02 per share and revenue of $23.25 billion. These totals would mark changes of +11.45% and +1.78%, respectively, from last year.
It is also important to note the recent changes to analyst estimates for AMGN. These revisions help to show the ever-changing nature of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.41% higher within the past month. AMGN is holding a Zacks Rank of #2 (Buy) right now.
Digging into valuation, AMGN currently has a Forward P/E ratio of 13.4. This represents a discount compared to its industry's average Forward P/E of 26.
Also, we should mention that AMGN has a PEG ratio of 1.82. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. Medical - Biomedical and Genetics stocks are, on average, holding a PEG ratio of 1.78 based on yesterday's closing prices.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 85, which puts it in the top 33% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.